| 8:00 | Conference Registration and Morning Coffee |
| 8:30 |
Chairpersons' Welcome and Opening Remarks
Edward Abrahams, PhD, Executive Director,
PERSONALIZED MEDICINE COALITION STATE OF INDUSTRY KEYNOTE
|
| 8:45 |
Overview: How Pharmacogenomics Is Improving Drug Development Success
Nadine Cohen, PhD, Head of Pharmacogenomics and Senior Research Fellow,
JOHNSON & JOHNSON Pharmaceutical Research and Development East Coast and Europe
|
| 9:30 |
Case Study
Understanding How and Why to Incorporate Pharmacogenomics in Clinical Studies
Mark Watson, PhD, Clinical Pharmacogenetics,
GLAXOSMITHKLINE
|
| 10:15 | Morning Break |
| 10:45 |
Applying Pharmacogenomics to the Drug Development Process for Safer More Effective Therapies
Moderated By:
David Johnston, PhD, Vice President, Chief Scientific Officer,
LABCORP
Nadine Cohen, PhD, Head of Pharmacogenomics and Senior Research Fellow,
JOHNSON & JOHNSON
Mark Watson, PhD, Clinical Pharmacogenetics,
GLAXOSMITHKLINE
|
| 11:30 |
Featured FDA Presentation
Collaborate on Novel Approaches to Diagnostics as They Evolve — FDA Recommendations for Pharmacogenomics
Courtney Harper, Associate Director for Toxicology, Division of Chemistry and Toxicology Devices,
CDRH, FDA
|
| 12:15 | Networking Luncheon |
| 1:30 |
Assay Development and Validation
Evaluation of Analytical Methods for RNA Extraction and Validation of the Affymetrix Microarray Platform for Clinical Application
Sunil Kadam PhD, Principle Research Scientist Genomic Medicine, Laboratory of Experimental Medicine,
ELI LILLY AND COMPANY
|
| 2:15 |
Featured Case Study
The Irinotecan Example- From Research to Market with a New Diagnostic Test for Irinotecan
Luis Parodi, PhD, Director and Site Head, Clinical Pharmacogenomics,
PFIZER
|
| 3:00 | Afternoon Networking Break |
| 3:30 |
Case Study
Development, Validation, and Clinical Study of Therapeutic and Diagnostic Oncology Biomarker
Ginette Serrero, PhD, President and Chief Scientific Officer,
A&G PHARMACEUTICALS
|
| 4:00 |
Genotyping Genetic Polymorphisms in Drug Metabolic Enzyme and Transporter Genes, Using the MegAllele Genotyping Platform
Carmen Dumaual, Associate, Diagnostic and Experimental Medicine,
ELI LILLY AND COMPANY
|
| 4:30 |
Panel Discussion
Incorporating Biomarker Validation and Qualification in Drug Development
Panelists:
Luis Parodi, PhD, Director and Site Head, Clinical Pharmacogenomics,
PFIZER
Ginette Serrero, PhD, President and Chief Scientific Officer,
A&G PHARMACEUTICALS
Carmen Dumaual, Associate, Diagnostic and Experimental Medicine,
ELI LILLY AND COMPANY
|
| 5:00 |
Day One Concludes
|
|
